The Foundation for Neglected Disease Research (FNDR) and DevsHealth have embarked on a collaborative effort to tackle flavivirus infections, including dengue, Zika, West Nile virus, and Japanese encephalitis. These infections, caused by flaviviruses within the Flaviviridae virus family, impact millions of individuals globally, particularly in low- and middle-income countries. While many cases are mild, severe forms can lead to life-threatening conditions such as haemorrhagic fever and encephalitis. The economic burden of these diseases is substantial, with climate change contributing to the spread of flavivirus infections in regions like Europe and North America.
The absence of effective drugs for flavivirus infections underscores the critical need for new treatment options. The collaboration between FNDR and DevsHealth aims to revolutionize the approach to these infections by not only developing broad-spectrum antiviral agents but also ensuring their affordability and accessibility to those in need, especially in low- and middle-income countries. DevsHealth, leveraging AI/ML technologies alongside real-world data and molecular modeling, will combine forces with FNDR, a not-for-profit organization specializing in drug discovery for infectious and neglected diseases.
DevsHealth’s expertise in in silico studies and chemistry efforts will complement FNDR’s capabilities in conducting in vitro and in vivo experiments. By integrating AI/ML technologies with traditional drug discovery methods, the consortium anticipates accelerating the identification and development of novel antiviral drugs for mosquito-borne neglected diseases. This collaboration aligns with DevsHealth’s mission of leveraging technology for societal benefit and FNDR’s commitment to combatting infectious diseases through innovative research and development.
The partnership underscores the importance of merging cutting-edge technology with scientific expertise to address global health challenges effectively. By harnessing AI/ML tools in drug development, the collaboration between FNDR and DevsHealth represents a significant step towards combating flavivirus infections and improving healthcare outcomes in regions heavily impacted by these diseases. The combination of DevsHealth’s DeepTech platform with FNDR’s research capabilities positions the consortium at the forefront of antiviral drug discovery, offering hope for more accessible and affordable treatments for mosquito-borne infections.
Key Takeaways:
– FNDR and DevsHealth are collaborating to develop affordable and accessible drugs for flavivirus infections using AI/ML technology.
– Flavivirus infections pose a significant global health burden, particularly in low- and middle-income countries.
– The partnership aims to accelerate the discovery of broad-spectrum antiviral agents effective against multiple flaviviruses.
– By integrating AI/ML technologies with traditional drug discovery approaches, the collaboration seeks to revolutionize treatment options for mosquito-borne neglected diseases.
Tags: clinical trials, biotech
Read more on news.webindia123.com